The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
Open accessAbstract
// Eloah Rabello Suarez 1, 2, 3 , De-Kuan Chang 1, 2 , Jiusong Sun 1, 2 , Jianhua Sui 4 , Gordon J. Freeman 2, 5 , Sabina Signoretti 6 , Quan Zhu 1, 2 , Wayne A. Marasco 1, 2 1 Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA 2 Department of Medicine, Harvard Medical School, Boston, MA, USA 3 Department of Biochemistry, Faculdade de Medicina do ABC, Av. Príncipe de Gales, SP, Brazil 4 National Institute of Biological Sciences, ZGC Life Science Park, Changping, Beijing, China 5 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 6 Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Correspondence to: Wayne A. Marasco, email: wayne_marasco@dfci.harvard.edu Keywords: immune checkpoint inhibitor, T cell exhaustion, chimeric antigen receptor, carbonic anhydrase IX, interleukin-21 Received: March 04, 2016 Accepted: April 16, 2016 Published: April 29, 2016 ABSTRACT Advances in the treatment of metastatic clear cell renal cell carcinoma (ccRCC) have led to improved progression-free survival of many patients; however the therapies are toxic, rarely achieve durable long-term complete responses and are not curative. Herein we used a single bicistronic lentiviral vector to develop a new combination immunotherapy that consists of human anti-carbonic anhydrase IX (CAIX)-targeted chimeric antigen receptor (CAR) T cells engineered to secrete human anti-programmed death ligand 1 (PD-L1) antibodies at the tumor site. The local antibody delivery led to marked immune checkpoint blockade. Tumor growth diminished 5 times and tumor weight reduced 50–80% when compared with the anti-CAIX CAR T cells alone in a humanized mice model of ccRCC. The expression of PD-L1 and Ki67 in the tumors decreased and an increase in granzyme B levels was found in CAR T cells. The anti-PD-L1 IgG1 isotype, which is capable of mediating ADCC, was also able to recruit human NK cells to the tumor site in vivo . These armed second-generation CAR T cells empowered to secrete human anti-PD-L1 antibodies in the ccRCC milieu to combat T cell exhaustion is an innovation in this field that should provide renewed potential for CAR T cell immunotherapy of solid tumors where limited efficacy is currently seen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“An Fc-engineered anti-PD-L1 mAb that lacks FcγR engagement has shown tumor regression in RCC, with a 12% of objective response rate, 41% stable disease lasting at least 24 weeks and 53% of progression-free survival at 24 weeks [4].”
BackgroundChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Self-citationFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,528
Self-citationToxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Varghese, F., Bukhari, A. B., Malhotra, R., & De, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096801 · Cited by 1,318
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
T-cell regulation by CD28 and CTLA-4
Alegre, M.-L., Frauwirth, K. A., & Thompson, C. B. (2001) · Nature Reviews Immunology · doi:10.1038/35105024 · Cited by 914
Lamers, C. H., Sleijfer, S., van Steenbergen, S., van Elzakker, P., van Krimpen, B., Groot, C., Vulto, A., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.17 · Cited by 704
Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697
John, L. B., Devaud, C., Duong, C. P. M., Yong, C. S., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 694
Engineering CAR-T cells: Design concepts
Srivastava, S., & Riddell, S. R. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.06.004 · Cited by 485
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
Hinrichs, C. S., Spolski, R., Paulos, C. M., Gattinoni, L., Kerstann, K. W., Palmer, D. C., Klebanoff, C. A., Rosenberg, S. A., Leonard, W. J., & Restifo, N. P. (2008) · Blood · doi:10.1182/blood-2007-09-113050 · Cited by 462
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
Das, R., Verma, R., Sznol, M., Boddupalli, C. S., Gettinger, S. N., Kluger, H., Callahan, M., Wolchok, J. D., Halaban, R., Dhodapkar, M. V., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401686 · Cited by 461
Lamers, C. H. J., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., Oosterwijk, E., Sleijfer, S., Debets, R., & Gratama, J. W. (2011) · Blood · doi:10.1182/blood-2010-07-294520 · Cited by 368
Isotype selection in antibody engineering
Salfeld, J. G. (2007) · Nature Biotechnology · doi:10.1038/nbt1207-1369 · Cited by 239
Crosstalk between Human IgG Isotypes and Murine Effector Cells
Overdijk, M. B., Verploegen, S., Ortiz Buijsse, A., Vink, T., Leusen, J. H. W., Bleeker, W. K., & Parren, P. W. H. I. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200356 · Cited by 229
Sedlakova, O. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2013.00400 · Cited by 202
Singh, H., Figliola, M. J., Dawson, M. J., Huls, H., Olivares, S., Switzer, K., Mi, T., Maiti, S., Kebriaei, P., Lee, D. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3843 · Cited by 199
CAR T Cells for Solid Tumors: Armed and Ready to Go?
Kakarla, S., & Gottschalk, S. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000032 · Cited by 190
Carbonic Anhydrase IX: Regulation and Role in Cancer
Benej, M., Pastoreková, S., & Pastorek, J. (2013) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-7359-2_11 · Cited by 161
Tostain, J., Li, G., Gentil‐Perret, A., & Gigante, M. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.020 · Cited by 143
The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer
Lee, D. W., Barrett, D. M., Mackall, C. L., Orentas, R. J., & Grupp, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1920 · Cited by 128
Mahoney, K. M., Sun, H. H., Liao, X., Hua, P., Callea, M., Greenfield, E. A., Hodi, F. S., Sharpe, A. H., Signoretti, S., Rodig, S. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0116 · Cited by 124
Self-citationMirzabekov, T. A., Kontos, H., Farzan, M., Marasco, W. A., & Sodroski, J. (2000) · Nature Biotechnology · doi:10.1038/76501 · Cited by 110
Self-citationHsu, C. Y. M., & Uludağ, H. (2012) · Nature Protocols · doi:10.1038/nprot.2012.038 · Cited by 110
Xu, D., Gu, P., Pan, P., Li, Q., Sato, A. I., & Chen, S. (2004) · International Journal of Cancer · doi:10.1002/ijc.11696 · Cited by 110
Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy
Adachi, K., & Tamada, K. (2015) · Cancer Science · doi:10.1111/cas.12695 · Cited by 99
Lamers, C. H. J., Langeveld, S. C. L., Ruijven, C. M. G.-V., Debets, R., Sleijfer, S., & Gratama, J. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0330-3 · Cited by 94
B7-H1 Expressed by Activated CD8 T Cells Is Essential for Their Survival
Pulko, V., Harris, K. J., Liu, X., Gibbons, R., Harrington, S. M., Krco, C. J., Kwon, E. D., & Dong, H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003976 · Cited by 86
Xu, F., Xu, L., Wang, Q., An, G., Feng, G., & Liu, F. (2015) · PubMed · Cited by 83
Chang, D.-K., Sui, J., Geng, S., Muvaffak, A., Bai, M., Fuhlbrigge, R. C., Lo, A. S., Yammanuru, A., Hubbard, L., Sheehan, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0278 · Cited by 75
Self-citationChang, D.-K., Moniz, R. J., Xu, Z., Sun, J., Signoretti, S., Zhu, Q. K., & Marasco, W. A. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0384-3 · Cited by 72
Self-citationExogenous control of mammalian gene expression via modulation of translational termination
Murphy, G. J., Mostoslavsky, G., Kotton, D. N., & Mulligan, R. C. (2006) · Nature Medicine · doi:10.1038/nm1376 · Cited by 56
Zhu, Y., Tan, Y., Ou, R., Zhong, Q., Zheng, L., Du, Y., Zhang, Q., & Huang, J. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12602 · Cited by 54
PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond
Harshman, L. C., Drake, C. G., & Choueiri, T. K. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0193 · Cited by 50
Xu, C., Lo, A. S., Yammanuru, A., Tallarico, A. S. C., Brady, K. W., Murakami, A., Barteneva, N. S., Zhu, Q. K., & Marasco, W. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009625 · Cited by 47
Self-citationLo, A. S., Xu, C., Murakami, A., & Marasco, W. A. (2014) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2014.3 · Cited by 25
Self-citation
Cited by
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4195 · Cited by 833
CAR-NK cells: A promising cellular immunotherapy for cancer
Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800
“[106] Recent reports have shown that local secretion of anti-PD1 antibodies [107] or scFv [108] at the tumour site by engineered CAR-T cells achieved superior anti-tumour activity and reduced adverse effect compared with systemic therapy.”
Background
Metadata
- Authors
- Suarez, E. R., Chang, D.-K., Sun, J., Sui, J., Freeman, G. J., Signoretti, S., Zhu, Q., & Marasco, W. A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-04-29
- Volume
- 7
- Issue
- 23
- Pages
- 34341-34355
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2342747014
- Cited by
- 340
- References
- 47
- FWCI
- 12.36
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.